<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01538251</url>
  </required_header>
  <id_info>
    <org_study_id>ST261DM11005</org_study_id>
    <secondary_id>2011-004765-32</secondary_id>
    <nct_id>NCT01538251</nct_id>
  </id_info>
  <brief_title>Efficacy, Safety and Tolerability of Propionyl-L-Carnitine Hydrochloride in Patients With Mild Ulcerative Colitis</brief_title>
  <official_title>Randomized Multicenter International Study to Investigate the Safety and Efficacy of Propionyl-L-Carnitine Hydrochloride Modified Release Tablets in Patients Affected by Mild Ulcerative Colitis Under Oral Stable Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>sigma-tau i.f.r. S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>sigma-tau i.f.r. S.p.A.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the trial is to test safety, tolerability and efficacy of Propionyl-L-carnitine&#xD;
      modified release tablets 1g/die in reducing the symptoms of the disease with respect to the&#xD;
      proportion of patients with disease remission at the end of the 8 weeks of treatment. It will&#xD;
      also aim to investigate capability of the treatment in the maintenance of remission after&#xD;
      four weeks of treatment interruption; histological changes will be also evaluated and&#xD;
      finally, improvement in the overall quality of life as measured by the Short Inflammatory&#xD;
      Bowel Disease Questionnaire (SIBDQ)will be investigated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Although it seems clear that an abnormal function of the colonic epithelium is the central&#xD;
      problem causing inflammation and the unusual immunological response to the normal gut flora&#xD;
      in inflammatory bowel disease (IBD), the actual causes of these dysfunctions are still&#xD;
      unknown.&#xD;
&#xD;
      Short Chain Fatty Acids (SCFA) are the main fuel of the colonic epithelium, and are normally&#xD;
      produced by the bacterial flora by fermentation of the complex carbohydrates forming non&#xD;
      soluble fibers usually introduced with everyday diet. Butyrate alone contributes 70% of the&#xD;
      normal colonocyte energy.&#xD;
&#xD;
      Studies done using animal models and colonic mucosa biopsies from patients suffering form&#xD;
      ulcerative colitis (UC) have consistently shown that a metabolic change occurs in diseased&#xD;
      colonic mucosa, with an impairment of butyrate oxidation (and of beta-oxidation) and an&#xD;
      energy shortage that is only incompletely compensated by oxidation of glucose and other&#xD;
      substrates such as glutamine.&#xD;
&#xD;
      It is also well known that matrix metalloproteases production is highly increased in IBD and&#xD;
      that serum transglutaminase activity is significantly reduced in patients with IBD.&#xD;
&#xD;
      Transglutaminases are enzymes contributing to the crosslinking of matrix proteins and the&#xD;
      reduction seen in patients affected by IBD correlates well with the endoscopic and&#xD;
      histopathologic grading in UC, meaning that part of the circulating enzyme is sequestered in&#xD;
      the injured colonic tissue in the effort to re-build the extracellular matrix during the&#xD;
      healing process.&#xD;
&#xD;
      Propionyl-L-carnitine Hydrochloride (PLC) is a molecule that has already been shown to reduce&#xD;
      membrane lipid peroxidation in endothelial cells from bovine aorta and coronary vessels, to&#xD;
      reduce the effects of hypoxia in coronary endothelial cells, and to play a role in the&#xD;
      cardiac metabolic abnormalities that contribute to the mechanical dysfunctions leading to&#xD;
      heart failure.&#xD;
&#xD;
      Given these properties of Propionyl-L-carnitine Hydrochloride (ST 261) and given the&#xD;
      peroxidative damage suffered by colonocytes in UC together with their metabolic impairment,&#xD;
      the use of this molecule for the treatment of UC seemed to be appropriate and sound, in&#xD;
      particular as a carrier of a propionate moiety that, once transformed into succinate, enters&#xD;
      the Kreb cycle, acting as an extra burst fuel improving the balance of energy production&#xD;
      inside tissues.&#xD;
&#xD;
      Previous clinical experience has shown that PLC promoted complete or nearly complete&#xD;
      regression of cutaneous trophic ulcers in a large number of vasculopathic patients refractory&#xD;
      to all other therapies.&#xD;
&#xD;
      As far as the UC pathology is concerned, the effects of ST 261, given orally or&#xD;
      intrarectally, were investigated at different dosages, in preclinical experimentation, either&#xD;
      after a single trinitrobenzene sulphonic acid (TNBS) administration (acute colitis) or after&#xD;
      repeated TNBS administrations (reactivated colitis). The results showed a reduction in the&#xD;
      damaged colon area both in acute model and reactivated colitis, even if the beneficial effect&#xD;
      of restoration of TNBS-induced alterations of tissue morphology is more evident in the&#xD;
      reactivated colitis model, particularly after oral administration.&#xD;
&#xD;
      Based on the above-described results a development plan in humans started to investigate the&#xD;
      activity of PLC in the treatment of ulcerative colitis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Evidence of very low probability to success. No safety issues.&#xD;
  </why_stopped>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of clinical/endoscopic remissions</measure>
    <time_frame>End of treatment (week 8)</time_frame>
    <description>Remission will be defined according with the overall modified Mayo score (Disease Activity Index). A score â‰¤ 2 with rectal bleeding sub-score = 0 and no other individual sub-score &gt;1 will be considered necessary to classify the patient in remission state.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Rectal bleeding evaluation</measure>
    <time_frame>At week 2, 6 and 8 of treatment and after 4 week follow-up</time_frame>
    <description>Evaluation will be performed by means of Disease Activity Index (DAI) sub-score (from 0 to 3).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in stool frequency evaluation</measure>
    <time_frame>At week 2, 6 and 8 of treatment and after 4 week follow-up</time_frame>
    <description>Evaluations will be performed by means of Disease Activity Index (DAI) sub-score (from 0 to 3).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histological response to the treatment</measure>
    <time_frame>End of treatment (week 8)</time_frame>
    <description>Evaluated as an improvement of the histological index of at least 1 point</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in C-reactive protein (CRP) and Fibrinogen</measure>
    <time_frame>End of the treatment (week 8) and after 4 week follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of patients quality of life</measure>
    <time_frame>End of treatment period (week8) and after 4 week follow-up</time_frame>
    <description>A validated specific questionnaire, the SIBDQ by McMaster university will be administered to evaluate changes in patients' quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haematology</measure>
    <time_frame>Baseline and end of treatment (week8)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrocardiogram</measure>
    <time_frame>At baseline and at the end of treatment period (week8)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events collection</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Chemistry</measure>
    <time_frame>At baseline and at the end of treatment period (week8)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">147</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>Propionyl-L-carnitine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>modified release tablets 500 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Modified release tablet 500 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propionyl-L-Carnitine</intervention_name>
    <description>Modified release tablets containing 500 mg of propionyl-L-carnitine. one tablet twice a day.</description>
    <arm_group_label>Propionyl-L-carnitine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablets containing 500 mg of propionyl-L-carnitine. one tablet twice a day.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have read the Information for the Patient and signed the Informed Consent Form.&#xD;
&#xD;
          -  Diagnosis of active ulcerative colitis since at least 4 weeks as confirmed&#xD;
             endoscopically and histologically.&#xD;
&#xD;
          -  Disease Activity Index comprised between 3 and 6, inclusive (mild ulcerative colitis),&#xD;
             with rectal bleeding sub-score of at least 1.&#xD;
&#xD;
          -  Stable background oral aminosalicylates (mesalazine, balsalazide, olsalazine) or&#xD;
             sulfasalazine standard therapy for greater than or equal to 4 weeks prior to screening&#xD;
             assessments.&#xD;
&#xD;
          -  If female, not pregnant or nursing. For women of childbearing potential, willingness&#xD;
             to avoid a pregnancy during the treatment period and for at least 4 weeks from the&#xD;
             last dose of drug and utilization of an efficient method of birth control for the&#xD;
             entire duration of the trial and until the first menses after a 30-day period after&#xD;
             the last dose of trial medication.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Crohn's disease and indeterminate colitis.&#xD;
&#xD;
          -  Current or previous (in the last 10 days preceding the screening) use of systemic&#xD;
             corticosteroids.&#xD;
&#xD;
          -  Use of systemic antibiotics in the last 10 days preceding the screening.&#xD;
&#xD;
          -  Use of systemic Nonsteroidal anti-inflammatory drugs on a repeat basis in the last 10&#xD;
             days preceding the screening.&#xD;
&#xD;
          -  Use of probiotics started within 10 days preceding the screening. A stable regimen&#xD;
             from at least 10 days prior to screening is allowed but the patient must be willing to&#xD;
             continue up to the end of the study.&#xD;
&#xD;
          -  Use of immunosuppressants or biological agents within the last 6 weeks preceding the&#xD;
             screening.&#xD;
&#xD;
          -  Treatment with L-carnitine or its esters derivatives within the last 3 months.&#xD;
&#xD;
          -  Stool culture positive for enteric pathogens (eg, Shigella, Salmonella, Yersinia,&#xD;
             Campylobacter) or toxins (C.difficile).&#xD;
&#xD;
          -  Significantly impaired liver, renal, pulmonary or cardiovascular function as assessed&#xD;
             by the investigator.&#xD;
&#xD;
          -  History of colon resection.&#xD;
&#xD;
          -  Diverticulitis, symptomatic diverticulosis.&#xD;
&#xD;
          -  Active peptic ulcer disease.&#xD;
&#xD;
          -  Proctitis (extent of inflammation &lt;15 cm from the anus).&#xD;
&#xD;
          -  Bleeding disorders&#xD;
&#xD;
          -  Rectal therapy with any therapeutic enemas or suppositories with the exception of&#xD;
             those required for endoscopy during the 10 days preceding the screening.&#xD;
&#xD;
          -  Active or chronic infection(s) or malignancies.&#xD;
&#xD;
          -  Known hypersensitivity to the active ingredient and excipients of the study drug.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandro Ardizzone, MD</last_name>
    <role>Study Director</role>
    <affiliation>Head of Inflammatory Bowel Diseases Unit Hospital &quot;Luigi Sacco&quot; Milan - ITALY</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Imelda Ziekenhuis</name>
      <address>
        <city>Bonheiden</city>
        <state>Antwerpen</state>
        <zip>2820</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaire Ziekenhuis Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <state>Flemish Brabant</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent</name>
      <address>
        <city>Ghent</city>
        <state>Oost-vlaanderen</state>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Hartziekenhuis Roeselare-Menen vzw</name>
      <address>
        <city>Roeselare</city>
        <state>West-vlaanderen</state>
        <zip>8800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Derma Plus s.r.o.</name>
      <address>
        <city>CeskÃ© Budejovice</city>
        <zip>370 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hepato-Gastroenterology HK s.r.o.</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>500 12</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FakultnÃ­ nemocnice Olomouc</name>
      <address>
        <city>Olomouc</city>
        <zip>775 20</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>G.E.P. Clinic s.r.o.</name>
      <address>
        <city>Praha 10</city>
        <zip>100 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MONSE s.r.o</name>
      <address>
        <city>Praha 1</city>
        <zip>118 33</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FakultnÃ­ Thomayerova nemocnice s poliklinikou</name>
      <address>
        <city>Praha 4 - Krc</city>
        <zip>140 59</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FakultnÃ­ Nemocnice v Motole</name>
      <address>
        <city>Praha 5</city>
        <zip>15006</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemocnice TÃ¡bor, a.s.</name>
      <address>
        <city>TÃ¡bor</city>
        <zip>390 03</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OrlickoÃºsteckÃ¡ Nemocnice a.s</name>
      <address>
        <city>ÃšstÃ­ nad OrlicÃ­</city>
        <zip>562 18</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soroka University Medical Center</name>
      <address>
        <city>Beer Sheva</city>
        <zip>84100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shaare Zedek Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <zip>91031</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hadassah Medical Organization, Ein Kerem</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meir Medical Center</name>
      <address>
        <city>Kfar-Saba</city>
        <zip>44281</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center</name>
      <address>
        <city>Petah Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaplan Medical Center</name>
      <address>
        <city>Rehovot</city>
        <zip>76100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tel Aviv Souraski Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Assaf Harofeh Medical Centre</name>
      <address>
        <city>Zerifin</city>
        <zip>70300</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale &quot;G.B.Morgagni - L. Pierantoni&quot;</name>
      <address>
        <city>ForlÃ¬</city>
        <state>Forli-cesena</state>
        <zip>47100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas</name>
      <address>
        <city>Rozzano</city>
        <state>Milano</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Luigi Sacco - Az. Osp. Dept. of Gastroenterology</name>
      <address>
        <city>Milano</city>
        <zip>20157</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Federico II</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCSS Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera S. Camillo Forlanini, Roma</name>
      <address>
        <city>Roma</city>
        <zip>00152</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Agostino Gemelli</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onze Lieve Vrouwe Gasthuis</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-holland</state>
        <zip>1091 AC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leids Universitair Medisch Centrum</name>
      <address>
        <city>Leiden</city>
        <state>Zuid-holland</state>
        <zip>2333 ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMC Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CMI de Gastroenterologie Dobru Daniela</name>
      <address>
        <city>Tirgu Mures</city>
        <state>Mures</state>
        <zip>540461</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neomed Research</name>
      <address>
        <city>Brasov</city>
        <zip>500283</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrul Medical Sana</name>
      <address>
        <city>Bucuresti</city>
        <zip>011025</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endocenter Medicina Integrativa SRL</name>
      <address>
        <city>Bucuresti</city>
        <zip>021978</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastromedica SRL</name>
      <address>
        <city>Iasi</city>
        <zip>700506</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Judetean De Urgenta Sibiu</name>
      <address>
        <city>Sibiu</city>
        <zip>550245</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinic Algomed SRL</name>
      <address>
        <city>Timisoara</city>
        <zip>300002</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Scientific Centre of Coloproctology</name>
      <address>
        <city>Moscow</city>
        <zip>123423</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Educational Institution of Higher Professional Education Novosibirsk State Medical University</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630091</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Research Institute of Physiology of Siberian Branch of Russian Academy of Medical Sciences</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630117</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GOU VPO Rostov State Medical University</name>
      <address>
        <city>Rostov-on-Don</city>
        <zip>344022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Petersburg GUZ City Policlinic 38</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>193015</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Military Clinical Hospital Â¿ 442 named after Z.P. Solovyov of Ministry of Defence of Russia</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>193124</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint-Petersburg State Institution of Health Protection City Hospital # 26</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>196247</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krestovsky Medical Institute</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197110</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saratov City Hospital #2</name>
      <address>
        <city>Saratov</city>
        <zip>410053</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint-Petersburg Medical Academy</name>
      <address>
        <city>St. Petersburg</city>
        <zip>195067</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Educational Institution of Higher Professional Education &quot;Stavropol State Medical Academy&quot;</name>
      <address>
        <city>Stavropol</city>
        <zip>355017</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital #2</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150010</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NovaMed spol. s.r.o.</name>
      <address>
        <city>BanskÃ¡ Bystrica</city>
        <zip>974 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNB Nemocnica StarÃ© Mesto</name>
      <address>
        <city>Bratislava</city>
        <zip>813 69</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ABAWI spol.s.r.o.</name>
      <address>
        <city>Bratislava</city>
        <zip>82101</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lama Medical Care s.r.o., Gastroentero-hepatologicke centrum Thalion</name>
      <address>
        <city>Bratislava</city>
        <zip>831 04</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NeÅ¡tÃ¡tna GastroenterologickÃ¡ Ambulancia</name>
      <address>
        <city>Bratislava</city>
        <zip>851 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KM Management sro</name>
      <address>
        <city>Nitra</city>
        <zip>950 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastro I.s.r.o.</name>
      <address>
        <city>PreÅ¡ov</city>
        <zip>08001</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GEA s.r.o Gastroenterologicka ambulancia</name>
      <address>
        <city>Trnava</city>
        <zip>91701</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czech Republic</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <study_first_submitted>February 20, 2012</study_first_submitted>
  <study_first_submitted_qc>February 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2012</study_first_posted>
  <last_update_submitted>November 4, 2016</last_update_submitted>
  <last_update_submitted_qc>November 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ulcerative colitis</keyword>
  <keyword>propionyl-l-carnitine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

